tirzepatide lymphedema For those asking if there is any research going on into the use of GLP1 injections and lymphoedema there is a study going on in America at present, they are recruiting 110 GLP-1 Medications (Ozempic®, Wegovy®, Mounjaro®,

How This Works FOXO4-DRI is a synthetic peptide that selectively targets senescent cells by blocking the FOXO4p53 protein interaction [1] [2]

Managing gallstone risk on Mounjaro Optimal weight loss rate The key to minimising gallstone risk is controlling your weight loss rate: Recommended targets: Week 1-4: 0.5-1 kg per week Week 5-12: 0.5-1 kg per week After 12 weeks: 0.5-1 kg per week Maximum safe rate: 1 kg per week Strategies to control weight loss rate: Start with the lowest dose (2.5 mg) Delay dose escalation if losing too quickly Ensure adequate calorie intake (maximum 10% deficit) Add protein-rich snacks if weight loss exceeds 1 kg/week Dietary strategies Specific dietary approaches can reduce gallstone risk during weight loss: Eat a diet based mainly on whole foods: Healthy fats: Include a portion the size of your thumb in each meal from nuts, meat, fish, olive oil, and dairy Fibre: Aim for half of your plate to come from vegetables Protein: Aim for a portion the size of an open hand in each meal Foods to moderate: Refined sugars and ultra-processed foods Take-aways Very low-fat diets ( 5 hours Fever with abdominal pain Yellowing of skin or eyes (jaundice) Dark urine and pale stools Medical monitoring requirements Baseline assessments Before starting Mounjaro with known gallstones: Essential tests: Complete medical history, including gallstone symptoms Physical examination Baseline weight and BMI Liver function tests (ALT, AST, ALP, bilirubin) Consider if indicated: Abdominal ultrasound if symptoms present Lipid profile Inflammatory markers if previous cholecystitis Follow-up schedule The following monitoring schedule represents expert practice suggestions rather than a fixed protocol: When to pause treatment Consider temporarily stopping Mounjaro if: Biliary colic episodes occur Liver function tests become abnormal Weight loss exceeds 2 kg per week consistently Severe gastrointestinal symptoms develop Pending gallbladder surgery Alternative weight loss options Other GLP-1 medications Different GLP-1 medications may have varying gallbladder risk profiles

It prevents aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome P450 unit

First, both compounds affect liver metabolism and nutrient handling